MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Immuno-Oncology, Immunotherapy
Immetas Therapeutics
Attachments
Homepage •
Parents
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Immuno-Oncology, Immunotherapy
Industry: New Jersey
Venture Capital: Series A
Children
2020: Immetas Therapeutics Announces Series A Financing to Advance Research on Inflammation Pathways in Aging and Develop Therapeutics for Cancer and Inflammatory Disease
East Hanover, New Jersey
Immetas discovers and develops novel therapeutics that modulate the innate immune system to treat age-related cancers and inflammatory diseases. The company’s approach is based on emerging evidence that chronic low-grade inflammation is a fundamental process governing aging and age-related diseases and anchored in clinical evidence to mitigate development risk.
Immetas was founded by J. Gene Wang, MD, PhD, a veteran in discovery and translational drug development in immunology/ inflammation and oncology, and David Sinclair, PhD, Professor of Genetics at Harvard Medical School and a leader in the molecular mechanisms of aging.
J. Gene Wang, MD, PhD, co-founder and CEO (2020)